Opus Genetics, Inc. (IRD)vsModerna Inc (MRNA)
IRD
Opus Genetics, Inc.
$3.85
+1.32%
HEALTHCARE · Cap: $336.94M
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 22506% more annual revenue ($2.23B vs $9.86M). IRD leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
IRD
Avoid19
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+29.1%
Fair Value
$4.64
Current Price
$3.85
$0.79 discount
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IRD profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 0.90 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
IRD generates stronger free cash flow (-12M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 19/100). IRD offers better value entry with a 29.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge gene-editing techniques and a strong research framework, Opus Genetics seeks to address significant unmet medical needs in ocular health. The company's innovative pipeline, bolstered by ongoing clinical trials and strategic partnerships, positions it favorably within the dynamic healthcare sector, offering substantial growth potential for institutional investors.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?